Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver Injury
Additionally, we continue to actively pursue in-licensing opportunities for clinical-stage assets.” About RAPT Therapeutics, Inc. RAPT Therapeutics is a clinical-stage, immunology-based therapeutics ...
U.S. FDA proposes ending use of popular decongestant present in cold medicines
The U.S. Food and Drug Administration has proposed to remove oral phenylephrine, widely used in cold and cough syrups, as an ...
FDA proposes removing ineffective decongestant found in most cold medicine
FDA officials said an agency review of the available data found oral phenylephrine is not effective as a nasal decongestant ...
medtechdive4d
J&J wins FDA approval for Varipulse PFA system
J&J is the third medtech company to gain U.S. approval for pulsed field ablation, a new atrial fibrillation treatment seeing rapid adoption.
AskBio Receives FDA Rare Pediatric Disease and Orphan-Drug Designations for AB-1003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2I/R9
(AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced that AB-1003 (also known as LION-101) has received rare pediatric disease ...
Live Science on MSN4d
LED device treats leading cause of vision loss with light therapy, FDA says
The Food and Drug Administration will allow a new device to be marketed as a treatment for dry age-related macular ...